Schedule 13D ownership disclosure

Inhibrx Biosciences Inc

Common Stock, par value $0.0001 per share · CUSIP: 45720N103

Event date: 2024-06-03

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • The Jon F. Kayyem and Paige Gates-Kayyem Family TrustReported CIK 0001821293

    Shares: 509,360.00 · Class: 3.5%

  • Jon Faiz KayyemReported CIK 0001366268

    Shares: 1,149,046.00 · Class: 7.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0002007919-25-000015
Form type
SCHEDULE 13D/A
Filer
Inhibrx Biosciences, Inc.
CIK
CIK 2007919
Filed
Feb 26, 2025
Reporting period
Jun 03, 2024
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub